Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04079803 · ClinicalTrials.gov registry record · Phase 2
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
A Phase 2 study, sponsored by Cassava Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
NCT04079803 is a Phase 2 study that has completed, run by Cassava Sciences. The registered enrollment target is 64 participants.
The verdict
NCT04079803, a Phase 2 study, has completed, sponsored by Cassava Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
Study Summary
This is a Phase 2b, Randomized, Double-blind, Placebo-controlled, multiple dose study of PTI-125 in mild-to-moderate Alzheimer's disease patients.
Interventions
- DRUG Placebo oral tablet
- DRUG Simufilam 100 mg tablet
- DRUG Simufilam 50 mg oral tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2019-09-09 |
| Est. Completion | 2020-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04079803
The ClinicalTrials.gov registry entry for NCT04079803 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cassava Sciences, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo oral tablet is the first listed.
NCT04079803 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04079803 about?
NCT04079803 is a clinical study titled "PTI-125 for Mild-to-moderate Alzheimer's Disease Patients". This is a Phase 2b, Randomized, Double-blind, Placebo-controlled, multiple dose study of PTI-125 in mild-to-moderate Alzheimer's disease patients.
What is the current status of trial NCT04079803?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2019-09-09. Estimated completion is 2020-03-31.
What interventions are being tested in trial NCT04079803?
The interventions under investigation include: Placebo oral tablet (DRUG), Simufilam 100 mg tablet (DRUG), Simufilam 50 mg oral tablet (DRUG).
Who is sponsoring clinical trial NCT04079803?
This trial is sponsored by Cassava Sciences, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.